Summary
- Profile Type
- Technology offer
- POD Reference
- TOFR20250324001
- Term of Validity
- 24 March 2025 - 24 March 2026
- Company's Country
- France
- Type of partnership
- Investment agreement
- Commercial agreement with technical assistance
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A French biotech SME expert in microbiota analysis of low-biomass and complex samples beyond the gut, with strong expertise in skin, oral, and tissue microbiomes. It also excels in molecular biology and bioinformatics. Its advanced analyses support disease understanding, biomarker discovery, treatment development, and product impact assessment. The company seeks new customers and international partners (public or private) for European grant applications.
- Full Description
-
The study of the microbiota has become central to biomedical research, offering crucial insights into disease onset and progression, biomarker discovery, and the development of innovative treatments. While research has traditionally focused on the intestinal microbiota, microbiomes exist throughout the human body. These microbiomes, though more complex to analyze, present significant scientific and therapeutic potential by providing precise insights into disease mechanisms.
A French biotech SME is among the few global players specializing in the analysis of microbiota in low-biomass and complex samples beyond the gut. The company specializes in microbiome, metagenome, and microbiota analysis across a diverse range of human and animal samples, encompassing both low-biomass (e.g., tissues, tumors, skin) and high-biomass (e.g., gut, feces, saliva, lungs, and vagina) environments. It has developed a unique expertise in studying complex microbiomes, facilitating a deeper understanding of disease mechanisms and advancing predictive diagnostics and personalized medicine.
The company provides a comprehensive suite of microbiome analysis services, including wet lab processing, sequencing, bioinformatics, statistical analysis, and scientific support. Its strong expertise in molecular biology and bioinformatics enables it to deliver robust and precise results not only in microbiota characterization but also in other areas such as host transcriptomics, RNA sequencing (RNA-seq), and primer design for both prokaryotic and eukaryotic targets.
Actively engaged in collaborative research, the company is the principal private partner in two major international European-funded consortia (H2020 and ERDF). It has also secured multiple French government grants and has contributed to 52 peer-reviewed articles published in high-impact journals. These publications cover topics such as the role of the microbiome in cancer, hepatology, cardiometabolic diseases, infectious diseases, and Lyme disease.
The company’s expertise is applicable across all fields of health research, but it is particularly valuable in dermocosmetics, oral care, cancer research (e.g., tumor and liquid biopsy), and diseases where bacterial translocation plays a critical role, such as liver diseases, cardiometabolic diseases, HIV, autoimmune disorders, and inflammatory bowel disease (IBD). Its ability to analyze challenging sample types—including skin, saliva, swabs, body fluids, and small biopsies—positions it as a leader in the field.
The company's business model integrates microbiome analysis services with bioinformatics and molecular biology expertise, while also maintaining strong commitments to collaborative research. It supports the discovery of new disease mechanisms and biomarkers, contributing to advancements in personalized medicine and the identification of novel therapeutic targets.
The company actively seeks partnerships within European research projects, primarily as a key partner within consortia led by coordinating institutions. Additionally, it engages in commercial agreements requiring advanced technical expertise, further solidifying its position as a leading innovator in microbiome research. - Advantages and Innovations
-
The technological breakthrough of the company was perfected after 13 years of R&D. The analysis solutions are now used by research players all over the world as innovative tools for scientific discovery.
The company can analyze the microbiome in all types of samples and matrices but is the pioneer and a major actor of complex sample analysis with a dedicated and sample-specific contamination aware approach. The pipeline of analysis is really sensitive and exhaustive.
The technological platform and the scientific advice cover all steps of the analysis of human or animal samples. Expertise of the company is perfectly suitable for both experts of the microbiome which want to access new sample types or for clinicians, academic researchers and industrial without expertise of the field and needing a high-end technical and scientific support.
Studying the different microbiota of the organism, allows to obtain more exploitable data, to be closer to the disease mechanism, and to discover biomarkers accessible in liquid biopsy. - Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- Goal 17: Partnerships to achieve the Goal
- Goal 9: Industry, Innovation and Infrastructure
- IPR status
- IPR granted
Partner Sought
- Expected Role of a Partner
-
The company seeks partners in the fields of dermocosmetics, oral care, and biomedical research, particularly those focused on uncovering new disease mechanisms, identifying novel biomarkers for personalized medicine, and exploring innovative therapeutic targets.
Recognizing the fundamental role of the microbiome in virtually all areas of health sciences, the company collaborates with experts across diverse disciplines. However, its expertise is particularly well developed in dermocosmetics, oncology, hepatology, and infectious diseases, with a strong focus on Lyme disease and other tick-borne illnesses.
Potential partners include clinicians, academic institutions, and industrial actors requiring microbiome-related expertise, bioinformatics analysis, and data interpretation for their research and applications. This may involve:
• Research consortia and academic laboratories integrating metagenomics into their projects,
• Clinical teams managing patient cohorts affected by microbiome-related diseases,
• Industry players assessing the impact of their products on the microbiome.
Additionally, the company offers specialized analytical services to microbiota experts studying low-biomass samples and tumor microbiomes, as well as to researchers from other disciplines who require advanced bioinformatics pipelines and high-level support for microbiome analysis in both standard and challenging samples - Type and Size of Partner
- SME <=10
- SME 11-49
- SME 50 - 249
- Big company
- R&D Institution
- University
- Other
- Type of partnership
- Investment agreement
- Commercial agreement with technical assistance
- Research and development cooperation agreement
Dissemination
- Technology keywords
- 06002002 - Cellular and Molecular Biology
- 06002008 - Microbiology
- 06003001 - Bioinformatics
- 03004011 - Care, Hygiene, Beauty
- Market keywords
- 04009 - In vitro Testing, Trials
- 04010 - Microbiology
- 04006 - Cellular and Molecular Biology
- 07004002 - Health and beauty aids
- 05001007 - Other diagnostic
- Sector Groups Involved
- Health
- Targeted countries
- All countries